Detailed Narrative
Q2 FY26 Performance Overview
RPG Life Sciences reported a robust Q2 FY26, with revenue from operations increasing by 7.6% QoQ to INR181.7 crores. EBITDA also saw a 7.1% QoQ rise to INR43.6 crores, maintaining a healthy EBITDA margin of 24.0%. PBT before exceptional item📎s grew by 7.9% over the previous quarter. For H1 FY26, revenue grew by 3.8% YoY, and PAT (excluding exceptional item📎s) stood at 15.6% YoY, despite the impact of a fire incident on EBITDA.
Domestic Formulations Business Outperforms Market
The domestic formulations business, contributing over 70% of total business, demonstrated strong growth. In Q2 FY26, it grew by 17.2% YoY, significantly outpacing the Indian pharmaceutical market's growth of 7.7%. For H1 FY26, the segment grew 13.5% YoY against the market's 7.4%. This strong performance led to an improvement in IPM ranking by 6 places, moving from 62 to 56.
International Formulations and API Business Update
The international formulations business, accounting for 20% of revenue, grew by 7.0% in Q2 FY26. The API business, which contributes 9%, faced headwinds in H1 due to a fire incident in January, resulting in an estimated sales loss of INR16 crores. However, the API plant restoration is on time and on budget, with commercialization expected by November last week or December first week, and API sales are projected to be back on track by year-end.
Strategic Initiatives and Digital Transformation
RPG Life Sciences is undergoing transformation through initiatives like the LEAP Project for cost optimization and margin expansion, Project Velocity for international business expansion, and Project Elevate for portfolio optimization. Digital initiatives include automating the field force, enhancing the RPGserv 2.0 doctor engagement platform with AI, and digitizing finance processes. The company also has 3 R&D setups for formulations, API, and analytical R&D, with a good pipeline of new products.
Product Portfolio and Growth Drivers
Key brands like Naprosyn, the largest in pain management, grew 16% Y-o-Y in H1 FY26 and is on track to become an INR100 crores brand. The immunosuppressant portfolio, including Azoran and Mofetil, grew 12% in H1 and is targeted to reach INR100 crores, then INR200 crores. The 'hidden gem' strategy is revitalizing legacy brands like Norpace, which grew 62% in H1, and Serenace, with efforts focused on increasing awareness and detection for conditions like ventricular hypertrophy.
Capital Allocation and Financial Health
The company maintains a strong balance sheet, remaining debt-free with a cash surplus that has grown to approximately INR223 crores. This financial strength, coupled with an ICRA rating of A+ (stable outlook), empowers the pursuit of both organic and inorganic growth opportunities across formulations and APIs. The company is actively exploring value-accretive acquisitions while being prudent about valuations.
Gross Margin Dynamics and MABs Segment
Gross margins have seen some compression, partly due to the INR16 crores sales loss from the API fire incident and the inability to feed captive consumption. Additionally, the MABs (Monoclonal Antibodies) segment is experiencing margin pressure due to increased competition and price wars as more companies enter the biological space. The strategy for MABs is to accelerate volume-backed growth to offset pricing pressure.